# Ultragenyx Pharmaceutical Inc.

Type: Company (RARE)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ultragenyx-pharmaceutical-inc
Canonical HTML page: https://getbiobrief.com/entity/ultragenyx-pharmaceutical-inc

## Timeline

- **2026-Q3**: Motion to Dismiss Phase — Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
- **2026-04-15**: Lead Plaintiff Deadline (Est.) — Typical 60-day window for investors to petition the court to lead the consolidated class action.
- **2026-03-12**: Litigation Commencement — Schall Law Firm announces class action lawsuits against both SLNO and RARE.
- **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
- **2026-02-26**: Soleno Executive Turnover — Official filing confirms the departure of several directors and officers.
- **2026-02-25**: Soleno Financial Results — Soleno files annual results and operational updates.
- **2026-02-12**: Ultragenyx Restructuring Disclosure — Company files SEC report detailing costs for exit or disposal activities.

## Recent coverage (2 stories)

### Schall Law Firm Targets Soleno and Ultragenyx in Securities Fraud Litigation
2026-03-12 10:06:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts.
Full story: https://getbiobrief.com/story/soleno-ultragenyx-securities-fraud-lawsuits-schall

### Pomerantz Law Firm Issues Class Action Deadlines for Major Biotech Firms
2026-03-05 23:21:15 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Full story: https://getbiobrief.com/story/pomerantz-biotech-class-action-deadlines-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.